Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its KRAS-mutated metastatic colorectal cancer (mCRC) program, with patient numbers increasing from 14 to 48. Initial data showed a robust objective response rate of 35% and a median progression-free survival (mPFS) of 9.4 months. A $15 million equity investment from Pfizer at a premium of 19% per share further supports the company's growth. Total operating expenses for Q4 2021 increased to $9.6 million, largely due to ongoing clinical programs. The company ended 2021 with approximately $141 million in cash.

On January 31, 2022, Cardiff Oncology (Nasdaq: CRDF) announced the granting of stock options to a new employee, totaling 55,008 shares. The options, priced at $3.38 per share, reflect the stock's closing price on the grant date. These inducements are in compliance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, contingent on the employee's continued employment. Cardiff Oncology focuses on innovative cancer treatments, including its investigational drug, onvansertib, targeting KRAS-mutated cancers and other high-need indications.

Cardiff Oncology, a clinical-stage oncology company targeting unmet medical needs in cancer treatment, announced its participation in the B. Riley Securities 2022 Oncology Conference, scheduled for January 27-28, 2022. The company will present on January 28, 2022, at 2:00 PM ET. Their lead investigational drug, onvansertib, is a first-in-class Polo-like Kinase 1 (PLK1) inhibitor, currently evaluated in three clinical programs focused on KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. A replay of the presentation will be available post-conference.

Cardiff Oncology (Nasdaq: CRDF) has released new data regarding its lead clinical trial of onvansertib combined with FOLFIRI/bevacizumab for treating KRAS-mutated metastatic colorectal cancer (mCRC). The Phase 1b/2 trial shows significant efficacy with 34% initial complete or partial responses among patients at the recommended dose and 94% achieving disease control. Notably, the median progression-free survival is reported at 9.4 months, exceeding historical controls. Results will be highlighted at the ASCOGI symposium on January 22, 2022.

Cardiff Oncology (Nasdaq: CRDF) has appointed Tod Smeal, Ph.D., as chief scientific officer and Charles Monahan, RPh, as senior vice president of regulatory affairs, as it advances its treatment pipeline. Smeal brings over 20 years of experience in targeted therapies, crucial for the development of onvansertib, a first-in-class Polo-like Kinase 1 inhibitor aimed at difficult-to-treat cancers. Monahan's regulatory expertise will facilitate the drug's journey towards approval. The company is focused on unmet needs in KRAS-mutated colorectal cancer and other severe cancers, aiming for improved patient outcomes.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced a conference call and webcast on January 18, 2022, at 5:00 PM ET, to discuss updated data from its lead clinical program in KRAS-mutated metastatic colorectal cancer. The data will also be featured at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), happening from January 20-22, 2022 in San Francisco. Cardiff is developing onvansertib, a first-in-class Polo-like Kinase 1 inhibitor, to improve cancer treatment outcomes in various indications.

Cardiff Oncology (Nasdaq: CRDF) announced its participation at the H.C. Wainwright BioConnect Virtual Conference from January 10 to 13, 2022. The presentation will be available on-demand starting at 7:00 AM ET on January 10. Cardiff Oncology focuses on developing precision medicine for cancer patients, specifically targeting KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Their investigational drug, onvansertib, is a third-generation Polo-like Kinase 1 inhibitor designed to improve treatment responses and overall survival.

Cardiff Oncology, a clinical-stage oncology company, announced updated data on its KRAS-mutated metastatic colorectal cancer program will be presented at the ASCO-GI from January 20-22, 2022, in San Francisco. The poster presentation titled "A phase 1b/2 trial of the PLK1 inhibitor onvansertib..." will showcase findings related to onvansertib in combination with FOLFIRI-bev for treating KRAS-mutated metastatic colorectal cancer. The abstract will be published on January 18, 2022, and is part of Poster Session C on January 22, 2022.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the grant of non-qualified stock options for 200,112 shares to two new employees on December 2, 2021. The options, set at an exercise price of $5.46 per share, will vest over four years, with 25% vesting after one year. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent in the oncology-focused firm. Cardiff is developing precision medicine for high-need cancer indications, including KRAS-mutated colorectal cancer and pancreatic cancer.